SIG is active in clinical research - looking for subjects with chronic constipation, IBS, Crohn


A Phase 3, Multicenter, Randomized, Double-blind,Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis

Purpose: The objective of the RPC1063 clinical development program in UC is to demonstrate that RPC1063 administered orally is safe and effective in inducing and maintaining remission in patients with moderate to severe UC.

Patient Eligibility: Patients with moderate to severe ulcerative colitis

Sponsor: Receptos, Inc.

Contact: Candace Grasse, Clinical Research Professionals, Phone: 636-220-1200, cgrasse@clinicalresearchprofessionals.net; or Specialists in Gastroenterology 314-997-0554, EXT. 136

A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy

Purpose: The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.

Patient Eligibility: Patients with moderate to severe Crohns’ disease

Sponsor: Receptos, Inc.

Contact: Candace Grasse, Clinical Research Professionals, Phone: 636-220-1200, cgrasse@clinicalresearchprofessionals.net; or Specialists in Gastroenterology 314-997-0554, EXT. 136

Multicenter, prospective, randomized study comparing the diagnostic yield of colon capsule endoscopy versus computed tomographic colonography in a screening population (the TOPAZ study)

Purpose: This trial will evaluate the efficacy of colon capsule endoscopy (CCE) versus computed tomographic colonography (CTC) in the identification of colonic polyps in a screening population.

Patient Eligibility: Patients eligible for screening colonoscopy

Sponsor: Given Imaging, Inc.

Contact: Candace Grasse, Clinical Research Professionals, Phone: 636-220-1200, cgrasse@clinicalresearchprofessionals.net; or Specialists in Gastroenterology 314-997-0554, EXT. 136

Multicenter, prospective, randomized study to assess positive/negative agreement for lesions in the small bowel and colon comparing PillCam Small Bowel Colon (SBC) capsule versus ileocolonoscopy (IC) plus magnetic resonance enterography (MRE) in symptomatic or asymptomatic subjects with known Crohn’s disease (CD) and mucosal disease (BLINK)

Purpose: To assess positive/negative agreement for lesions in the small bowel and colon comparing PillCam Small Bowel Colon (SBC) capsule versus ileocolonoscopy (IC) plus magnetic resonance enterography (MRE) in symptomatic or asymptomatic subjects with known Crohn’s disease (CD) and mucosal disease.

Patient Eligibility: Patients with Crohns’ disease

Sponsor: Given Imaging, Inc.

Contact: Candace Grasse, Clinical Research Professionals, Phone: 636-220-1200, cgrasse@clinicalresearchprofessionals.net; or Specialists in Gastroenterology 314-997-0554, EXT. 136

Linzess for irritable bowel syndrome with constipation and chronic constipation

Purpose: The purpose of the study is to determine if antibodies form in the blood against the medicine. This medicine is FDA-approved for these conditions. There is no placebo for this study. All patients get the medicine Linzess for free. They are not allowed to participate if Linzess or Amitiza has been used in the past.

Sponsor: Actavis pharmaceutical

Contact: Dr. Weinstock's study coordinator at Sundance Research Center: 314-567-3377.

 

Use of SBI for the Maintenance of Health in Subjects With Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease, or Pouchitis

Purpose: The primary objective of this study is to determine whether giving oral serum bovine immunoglobulin (SBI) twice a day as a medical food when any other medical therapy fails or is partly effective. The maintenance of health in the management of these conditions are monitored in routine office visits at Specialists in Gastroenterology. These visits are paid by your own insurance coverage. SBI is the main ingredient in EnteraGam, an orally administered prescription medical food for the dietary management of patients with enteropathy or chronic loose or frequent stools, including patients with IBS-D.

Sponsor and Collaborator: Entera Health, Inc

Contact: Specialists in Gastroenterology – secretaries@gidoctor.net or contact your doctor at SIG